Overview

Phase I Clinical Trial of Tremelimumab Plus MEDI3617 in Patients With Unresectable Stage III or Stage IV Melanoma

Status:
Active, not recruiting
Trial end date:
2022-03-01
Target enrollment:
Participant gender:
Summary
This is an open label, phase I trial, testing the combination of Tremelimumab and MEDI3617 in patients with metastatic melanoma.
Phase:
Phase 1
Details
Lead Sponsor:
F. Stephen Hodi, MD
Collaborator:
MedImmune LLC
Treatments:
Antibodies, Monoclonal
Tremelimumab